Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis

PHASE2RecruitingINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

August 6, 2025

Primary Completion Date

February 29, 2028

Study Completion Date

March 31, 2028

Conditions
Lewy Body Dementia Psychosis
Interventions
DRUG

ACP-204

Provided as 1 capsule, to be taken orally once daily

DRUG

Placebo

Provided as 1 capsule, to be taken orally once daily

Trial Locations (13)

19001

RECRUITING

Abington Neurological Associates, LTD, Abington

32159

RECRUITING

K2 Summit Research, Lady Lake

33032

RECRUITING

Homestead Associates in Research Inc, Miami

33122

RECRUITING

Premier Clinical Research Institute, Inc., Miami

33135

RECRUITING

Advanced Clinical Research Network, Corp, Miami

33165

RECRUITING

MediClear Medical & Research Center, Inc., Miami

33180

RECRUITING

Humanity Clinical Research, Corp, Aventura

33407

RECRUITING

Health Synergy Clinical Research, LLC, West Palm Beach

34711

RECRUITING

K2 Medical Research Winter Garden LLC, Clermont

66160

RECRUITING

University of Kansas Medical Center Research Institute Inc., Kansas City

74136

RECRUITING

The Movement Disorder Clinic of Oklahoma, Tulsa

77477

RECRUITING

R and H Clinical Research, Stafford

92612

RECRUITING

ATP Clinical Research Inc., Irvine

Sponsors
All Listed Sponsors
lead

ACADIA Pharmaceuticals Inc.

INDUSTRY